---
document_datetime: 2023-09-21 18:35:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/topotecan-eagle-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: topotecan-eagle-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 0.9558326
conversion_datetime: 2025-12-31 02:02:05.65278
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Topotecan Eagle

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                             | Opinion/ Notification 1 issued on Commission Decision Issued 2 / amended on Information affected no   | Product 3   | Summary   |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------|-------------|-----------|
| IB/0001              | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) Product | 13/03/2012 04/10/2012                                                                                 | SmPC        |           |

<!-- image -->

Medicinal Product no longer authorised

<!-- image -->